Urine test may detect aggressive prostate tumors
Key points
- Researchers believe they have found a compound produced by aggressive prostate tumors and hope they can use it to design a urine test to detect the most dangerous tumors, they said Monday.
- Prostate cancer, which is found in 780,000 men every year globally and kills 250,000, can be very slow-growing.
- One difficulty is identifying the patients who need the most careful monitoring after surgery or radiation therapy to destroy the tumor.
- Scott Tomlins and colleagues at the University of Michigan Health System looked at 1,800 prostate tumors to try to identify the unique "signature" of an aggressive type of prostate cancer found in about 10 percent of patients.
Researchers believe they have found a compound produced by aggressive prostate tumors and hope they can use it to design a urine test to detect the most dangerous tumors, they said Monday.
Prostate cancer, which is found in 780,000 men every year globally and kills 250,000, can be very slow-growing. While common, it does not always require immediate treatment.
One difficulty is identifying the patients who need the most careful monitoring after surgery or radiation therapy to destroy the tumor.
Scott Tomlins and colleagues at the University of Michigan Health System looked at 1,800 prostate tumors to try to identify the unique "signature" of an aggressive type of prostate cancer found in about 10 percent of patients.
A gene called SPINK1 was over-expressed, or over-active, in about 44 percent of cases of prostate cancer, they reported in the journal Cancer Cell. Their findings suggested that cancer was twice as likely to come back after surgery among men with SPINK1-related prostate cancers.
Tumors recur after surgery in between 25 percent and 40 percent of men, the researchers said.
Because the gene can be detected in the urine, without any invasive procedures, a test could be developed to complement urine tests currently used to detect some prostate cancers, said Dr. Arul Chinnaiyan, who oversaw the research.
Tests include a blood test that looks for prostate-specific antigen (PSA), a protein produced only by prostate cells. Prostate tumors produce extra levels of PSA, but so does a prostate that is simply enlarging with age, making the test imprecise. Doctors also use digital rectal examination to detect irregularities.
San Diego-based Gen-Probe Inc. has a urine test to screen for a protein called PCA3, although it is not approved in the United States.
The University of Michigan has filed for a patent on SPINK1 as a "biomarker" for prostate cancer and licensed rights to Gen-Probe.
The researchers said they do not know precisely how SPINK1 is involved in cancer and will continue to investigate.
WASHINGTON (Reuters)
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsProstate cancer: A change in circulating tumor cells detection has high potential in the prediction
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific…
13 October 2013
NewsBlood tests could detect sexually-transmitted oral cancers
Antibodies to a high-risk type of a virus that causes mouth and throat cancers when transmitted via oral sex can be detected in blood tests many years before onset of the disease, according to a World Health…
18 June 2013
NewsBiomarker identification may lead to new noninvasive test for colorectal cancer detection
The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene…
